Peter Pushko

Summary

Publications

  1. Tretyakova I, Nickols B, Hidajat R, Jokinen J, Lukashevich I, Pushko P. Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice. Virology. 2014;468-470:28-35 pubmed publisher
    ..We conclude that iDNA immunization approach combines characteristics of DNA and attenuated vaccines and represents a promising vaccination strategy for YF. ..
  2. Pushko P, Tretyakova I, Hidajat R, Sun X, Belser J, Tumpey T. Multi-clade H5N1 virus-like particles: Immunogenicity and protection against H5N1 virus and effects of beta-propiolactone. Vaccine. 2018;36:4346-4353 pubmed publisher
  3. Pushko P, Kort T, Nathan M, Pearce M, Smith G, Tumpey T. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine. 2010;28:4771-6 pubmed publisher
    ..Moreover, a single 15mug dose of H1N1 VLPs resulted in complete virus clearance in the ferret lung. These results provide support for the use of recombinant influenza VLP vaccine as an effective strategy against pandemic H1N1 virus. ..
  4. Pushko P, Pujanauski L, Sun X, Pearce M, Hidajat R, Kort T, et al. Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus. Vaccine. 2015;33:4975-82 pubmed publisher
    ..Immunogenicity and protective efficacy of rH7 SVPs was confirmed in the mouse and ferret challenge models suggesting that SVPs can be used for vaccination against H7N9 virus. ..
  5. Tretyakova I, Hidajat R, Hamilton G, Horn N, Nickols B, Prather R, et al. Preparation of quadri-subtype influenza virus-like particles using bovine immunodeficiency virus gag protein. Virology. 2016;487:163-71 pubmed publisher
    ..Electron microscopy showed that Bgag-based VLPs resembled influenza virions with the diameter of 150-200nm. This is the first report of quadri-subtype design for influenza VLP and the use of Bgag for influenza VLP preparation. ..
  6. Hidajat R, Nickols B, Forrester N, Tretyakova I, Weaver S, Pushko P. Next generation sequencing of DNA-launched Chikungunya vaccine virus. Virology. 2016;490:83-90 pubmed publisher
    ..064% and 0.086%, while in the 181/25, frequencies were 0.179% and 0.133%, respectively. We conclude that the DNA-launched virus has a reduced probability of reversion mutations, thereby enhancing vaccine safety. ..
  7. Kapczynski D, Tumpey T, Hidajat R, Zsak A, Chrz─ůstek K, Tretyakova I, et al. Vaccination with virus-like particles containing H5 antigens from three H5N1 clades protects chickens from H5N1 and H5N8 influenza viruses. Vaccine. 2016;34:1575-1581 pubmed publisher
    ..S. H5N8 HPAI isolate. We conclude that these novel triple-clade VLPs represent a feasible strategy for simultaneously evoking protective antibodies against multiple variants of H5 influenza virus. ..
  8. Pushko P, Sun X, Tretyakova I, Hidajat R, Pulit Penaloza J, Belser J, et al. Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model. Vaccine. 2016;34:5235-5242 pubmed publisher
  9. Pushko P, Tretyakova I, Hidajat R, Zsak A, Chrz─ůstek K, Tumpey T, et al. Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens. Virology. 2017;501:176-182 pubmed publisher
    ..Immune response was also detectable after challenge with low pathogenicity AI (LPAI) H9N2 virus suggesting that H5/H7/H9/N1/gag VLPs represent a promising approach for the development of broadly protective AI vaccine. ..

More Information

Publications10

  1. Nickols B, Tretyakova I, Tibbens A, Klyushnenkova E, Pushko P. Plasmid DNA launches live-attenuated Japanese encephalitis virus and elicits virus-neutralizing antibodies in BALB/c mice. Virology. 2017;512:66-73 pubmed publisher
    ..The results demonstrate the possibility of using DNA vaccination to launch live-attenuated JEV vaccine and support further development of DNA-launched live-attenuated vaccine for prevention of JEV infections. ..